Opinion|Videos|July 8, 2024
Hidradenitis Suppurativa: Addressing the Psychosocial Impact and Hospitalization Rate
Author(s)Iltefat Hamzavi, MD
Dr Hamzavi discusses how clinicians can address the psychosocial impact of hidradenitis suppurativa on patients and the rate of hospitalization.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What is the psychosocial impact of HS and how can clinicians empower these patients?
- How is the rate of hospitalization due to HS changing over time and what can clinicians do to keep patients out of the hospital?
- How is the rate of hospitalization due to HS changing over time and what can clinicians do to keep patients out of the hospital?
Advertisement
Related to this article
Delphi consensus guides dermatology on spotting CTCL vs atopic dermatitis before/after dupilumab, using biopsy plus T-cell clonality testing and safer treatment switches.
Rosacea is likely missed, not rare, in skin of color, as low suspicion and hard-to-see redness delay diagnosis, said Hilary Baldwin, MD.
Hidradenitis suppurativa diagnosis often takes 7 to 10 years, and patients with skin of color often present with tunnels and scarring already in place.
Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.
Advertisement
Advertisement
Trending on AJMC
1
A New Mechanism for DME in the BRUNELLO Trial: Donald J. D’Amico, MD
2
Using Complement Inhibitors in GA Comes With Pros and Cons
3
Pairing VYD2311 With mRNA COVID-19 Vaccines: Michael Mina, MD, PhD
4
New Mechanism of DME Treatment Highlights Clinical Trial Updates
5